|
1
|
Lopez MS, Baker ES, Maza M, Fontes-Cintra
G, Lopez A, Carvajal JM, Nozar F, Fiol V and Schmeler KM: Cervical
cancer prevention and treatment in Latin America. J Surg Oncol.
115:615–618. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Canfell K, Kim JJ, Brisson M, Keane A,
Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Bénard É, et
al: Mortality impact of achieving WHO cervical cancer elimination
targets: A comparative modelling analysis in 78 low-income and
lower-middle-income countries. Lancet. 395:591–603. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnson CA, James D, Marzan A and Armaos
M: Cervical cancer: An overview of pathophysiology and management.
Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimet GD, Rosberger Z, Fisher WA, Perez S
and Stupiansky NW: Beliefs, behaviors and HPV vaccine: Correcting
the myths and the misinformation. Prev Med. 57:414–418. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang Z and Jiang X, Li D and Jiang X:
HBXIP promotes gastric cancer via METTL3-mediated MYC mRNA m6A
modification. Aging (Albany NY). 12:24967–24982. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zheng S, Wu H, Wang F, Lv J, Lu J, Fang Q,
Wang F, Lu Y, Zhang S, Xu Y, et al: The oncoprotein HBXIP
facilitates metastasis of hepatocellular carcinoma cells by
activation of MMP15 expression. Cancer Manag Res. 11:4529–4540.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao Y, Li H, Zhang Y, Li L, Fang R, Li Y,
Liu Q, Zhang W, Qiu L, Liu F, et al: Oncoprotein HBXIP modulates
abnormal lipid metabolism and growth of breast cancer cells by
activating the LXRs/SREBP-1c/FAS signaling cascade. Cancer Res.
76:4696–4707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiu L, Lu F, Zhang L, Wang G, Geng R and
Miao Y: HBXIP regulates gastric cancer glucose metabolism and
malignancy through PI3K/AKT and p53 signaling. Onco Targets Ther.
13:3359–3374. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang X, Feng Q, Yu H, Zhou X, Shan C,
Zhang Q and Liu S: HBXIP: A potential prognosis biomarker of
colorectal cancer which promotes invasion and migration via
epithelial-mesenchymal transition. Life Sci. 245:1173542020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiu M, Zeng X, Shan R, Wen W, Li J and Wan
R: The oncogenic role of HBXIP. Biomed Pharmacother.
133:1110452021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li N, Wang Y, Che S, Yang Y, Piao J, Liu S
and Lin Z: HBXIP over expression as an independent biomarker for
cervical cancer. Exp Mol Pathol. 102:133–137. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chan KK, Tsui SK, Lee SM, Luk SC, Liew CC,
Fung KP, Waye MM and Lee CY: Molecular cloning and characterization
of FHL2, a novel LIM domain protein preferentially expressed in
human heart. Gene. 210:345–350. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kinoshita M, Nakagawa T, Shimizu A and
Katsuoka Y: Differently regulated androgen receptor transcriptional
complex in prostate cancer compared with normal prostate. Int J
Urol. 12:390–397. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Genini M, Schwalbe P, Scholl FA, Remppis
A, Mattei MG and Schäfer BW: Subtractive cloning and
characterization of DRAL, a novel LIM-domain protein down-regulated
in rhabdomyosarcoma. DNA Cell Biol. 16:433–442. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu J, Zhou J, Li MS, Ng CF, Ng YK, Lai PBS
and Tsui SKW: Transcriptional regulation of the tumor suppressor
FHL2 by p53 in human kidney and liver cells. PLoS One.
9:e993592014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gabriel B, Mildenberger S, Weisser CW,
Metzger E, Gitsch G, Schüle R and Müller JM: Focal adhesion kinase
interacts with the transcriptional coactivator FHL2 and both are
overexpressed in epithelial ovarian cancer. Anticancer Res.
24:921–927. 2004.PubMed/NCBI
|
|
17
|
Chan KK, Tsui SK, Ngai SM, Lee SM, Kotaka
M, Waye MM, Lee CY and Fung KP: Protein-protein interaction of
FHL2, a LIM domain protein preferentially expressed in human heart,
with hCDC47. J Cell Biochem. 76:499–508. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen D, Xu W, Bales E, Colmenares C,
Conacci-Sorrell M, Ishii S, Stavnezer E, Campisi J, Fisher DE,
Ben-Ze'ev A and Medrano EE: SKI activates Wnt/beta-catenin
signaling in human melanoma. Cancer Res. 63:6626–6634.
2003.PubMed/NCBI
|
|
19
|
Jin H, Lee K, Kim YH, Oh HK, Maeng YI, Kim
TM, Suh DS and Bae J: Scaffold protein FHL2 facilitates
MDM2-mediated degradation of IER3 to regulate proliferation of
cervical cancer cells. Oncogene. 35:5106–5118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin X, Jiao X, Jiao J, Zhang T and Cui B:
Increased expression of FHL2 promotes tumorigenesis in cervical
cancer and is correlated with poor prognosis. Gene. 669:99–106.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao CY, Mok SWF, Cheng VWS and Tsui SKW:
The FHL2 regulation in the transcriptional circuitry of human
cancers. Gene. 572:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brun J, Dieudonné FX, Marty C, Müller J,
Schüle R, Patiño-García A, Lecanda F, Fromigué O and Marie PJ: FHL2
silencing reduces Wnt signaling and osteosarcoma tumorigenesis in
vitro and in vivo. PLoS One. 8:e550342013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Qie S and Diehl JA: Cyclin D1, cancer
progression, and opportunities in cancer treatment. J Mol Med
(Berl). 94:1313–1326. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hamidi H and Ivaska J: Every step of the
way: Integrins in cancer progression and metastasis. Nat Rev
Cancer. 18:533–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oudin MJ and Weaver VM: Physical and
chemical gradients in the tumor microenvironment regulate tumor
cell invasion, migration, and metastasis. Cold Spring Harb Symp
Quant Biol. 81:189–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nie H, Bu F, Xu J, Li T and Huang J: 29
immune-related genes pairs signature predict the prognosis of
cervical cancer patients. Sci Rep. 10:141522020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang FZ, Fei HR, Lian LH, Wang JM and Qiu
YY: Hepatitis B x-interacting protein induces HepG2 cell
proliferation through activation of the phosphatidylinositol
3-kinase/Akt pathway. Exp Biol Med (Maywood). 236:62–69. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li Y, Zhang Z, Zhou X, Li L, Liu Q, Wang
Z, Bai X, Zhao Y, Shi H, Zhang X and Ye L: The oncoprotein HBXIP
enhances migration of breast cancer cells through increasing
filopodia formation involving MEKK2/ERK1/2/Capn4 signaling. Cancer
Lett. 355:288–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Cui M, Cai X, Sun B, Liu F, Zhang
X and Ye L: The oncoprotein HBXIP up-regulates SCG3 through
modulating E2F1 and miR-509-3p in hepatoma cells. Cancer Lett.
352:169–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zheng K, He Z, Kitazato K and Wang Y:
Selective autophagy regulates cell cycle in cancer therapy.
Theranostics. 9:104–125. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fei H, Zhou Y, Li R, Yang M, Ma J and Wang
F: HBXIP, a binding protein of HBx, regulates maintenance of the
G2/M phase checkpoint induced by DNA damage and enhances
sensitivity to doxorubicin-induced cytotoxicity. Cell Cycle.
16:468–476. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang C, Lv X, He C, Davis JS, Wang C and
Hua G: Four and a half LIM domains 2 (FHL2) contribute to the
epithelial ovarian cancer carcinogenesis. Int J Mol Sci.
21:77512020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hua G, He C, Lv X, Fan L, Wang C, Remmenga
SW, Rodabaugh KJ, Yang L, Lele SM, Yang P, et al: The four and a
half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor
progression via controlling AKT1 transcription. Cell Death Dis.
7:e22972016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shao C, Qiu Y, Liu J, Feng H, Shen S,
Saiyin H, Yu W, Wei Y, Yu L, Su W and Wu J: PARP12 (ARTD12)
suppresses hepatocellular carcinoma metastasis through interacting
with FHL2 and regulating its stability. Cell Death Dis. 9:8562018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Duchartre Y, Kim YM and Kahn M: The Wnt
signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bahrami A, Amerizadeh F, ShahidSales S,
Khazaei M, Ghayour-Mobarhan M, Sadeghnia HR, Maftouh M, Hassanian
SM and Avan A: Therapeutic potential of targeting wnt/beta-catenin
pathway in treatment of colorectal cancer: Rational and progress. J
Cell Biochem. 118:1979–1983. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cai T, Sun D, Duan Y, Qiu Y, Dai C, Yang J
and He W: FHL2 promotes tubular epithelial-to-mesenchymal
transition through modulating beta-catenin signalling. J Cell Mol
Med. 22:1684–1695. 2018. View Article : Google Scholar : PubMed/NCBI
|
